Skip to main content
Figure 3 | World Journal of Surgical Oncology

Figure 3

From: CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion

Figure 3

PI3K and Akt activation by CCR9-CCL25 interactions. MDA-MB-231 cells were tested for their ability to activate PI3K and Akt following treatment with CCL25, cisplatin and specific kinase inhibitors (wortmannin and PF-573, 228). In situ total and active (phosphorylated) PI3K and Akt levels were quantified by Fast Activated Cell-based ELISA (FACE) assay before (0 minutes) or after (5 or 10 minutes) CCL25 stimulation in the presence of cisplatin and kinase inhibitors.

Back to article page